Centers | ||
|
|
|
Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Weccome Centre for Anti-Infectives Research | Therapeutic Accelerator Program (TAP) |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
WCAIR brings together the Drug Discovery Unit (DDU) , the Mode of Action group and the Parasitology research groups. With the daily interactions of these groups, parasitology and drug discovery can work together in synergy. This empowers us to create... Read more |
Test |
Partnerships |
Events |
Jobs |
Bayer and UCSF Enter into a 10year Research & Development PartnershipBayer and University of California, San Francisco (UCSF) have signed a 10year master research and development agreement. The agreement provides a broad template for collaboration between the two groups around common areas of research interest... View all Sanofi and Stanford's Bio-X to Collaborate on Early Stage ResearchSanofi and Stanford University's Bio-X have entered into a multi-year collaboration that support interdisciplinary collaborative research to be conducted at Stanford. A joint steering committee comprising of representatives from Stanford and... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |
